Reduction in oral mucosa micronuclei frequency following alpha-tocopherol treatment of oral leukoplakia.
Micronuclei frequency, a marker of genotoxicity, was studied within a trial of alpha-tocopherol for chemoprevention of oral leukoplakia. Oral swabs were obtained from two sites, the leukoplakia lesion and normal-appearing mucosa, at baseline and following 24 weeks of therapy with 400 international units of alpha-tocopherol twice daily. These specimens were analyzed for micronuclei frequency. The major risk factors for oral carcinogenesis in the group studied were cigarette smoking and alcohol consumption. alpha-tocopherol therapy produced a significant reduction in micronuclei frequencies in specimens from both the visible lesions (P < 0.01) and the normal-appearing mucosa (P < 0.01). The micronuclei frequencies, both at baseline and following therapy, were greater in specimens taken from the lesion than in those from the normal-appearing mucosa. Although these results indicate that alpha-tocopherol has a beneficial effect in oral carcinogenesis, there was no significant clinical or histological response associated with the change in micronuclei frequency. Micronuclei frequency has not yet been validated as a biomarker for cancer incidence, and consequently, its utility as an intermediate end point for chemoprevention trials is not known. Determining clinical significance of micronuclei frequency patterns in oral carcinogenesis and chemoprevention will require further study.
Benner
S E
SE
Division of Medicine, University of Texas M. D. Anderson Cancer Center, Houston 77030.
Wargovich
M J
MJ
Lippman
S M
SM
Fisher
R
R
Velasco
M
M
Winn
R J
RJ
Hong
W K
WK
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor; D005260:Female; D006801:Humans; D007972:Leukoplakia, Oral / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D048629:Micronuclei, Chromosome-Defective / Q000473:pathology*; D008875:Middle Aged; D009061:Mouth Mucosa / Q000473:pathology*; D015588:Observer Variation; D014810:Vitamin E / Q000627:therapeutic use*
D014408:Biomarkers, Tumor; D014810:Vitamin E